Time course changes of cystatin C and inflammatory and biochemical markers in non-ST-elevation acute coronary syndromes

Journal of Cardiovascular Medicine

Volumn 15, Issue 1, 2014, Pages 42-47

  De Servi, Stefano ^a   Mariani, Giuseppe ^a   Piatti, Luigi ^b   Leoncini, Mario ^c   Rubartelli, Paolo ^d   Pitì, Antonio ^e   Curello, Salvatore ^f   Galdangelo, Francesco ^g   Vandoni, Pietro ^h   Rossetti, Enrico ^a   Mariani, Matteo ^a   Boschetti, Enrico ⁱ   Re, Gianpietro ^j   Loznicker, Milvia ^j  

^a AO Ospedale Civile   (Italy)

^b A MANZONI HOSPITAL   (Italy)

^c MISERICORDIA E DOLCE HOSPITAL   (Italy)

^d Division of Cardiology   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f Cardiology Unit   (Italy)

^g Sant'Antonio Abate Hospital   (Italy)

^h DESIO HOSPITAL   (Italy)

ⁱ S MARIA HOSPITAL   (Italy)

^j Ospedale Civile di Legnano   (Italy)

more..

Author keywords

cystatin C; inflammatory prognostic markers; non ST elevation acute coronary syndrome

Indexed keywords

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYSTATIN C; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NECROSIS; PATIENT ADMISSION; PATIENT DISCHARGE; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN; VENTRICULAR FUNCTION, LEFT;

EID: 84894106110     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328365a275     Document Type: Article

References (29)

1. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40:221-226.
2. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16:1404-1412.
3. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141:929-937.
4. Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 2007; 53:480-488.
5. Deo R, Sotoodehnia N, Katz R, et al. Cystatin C and sudden cardiac death risk in the elderly. Circ Cardiovasc Qual Outcomes 2010; 3:159-164.
6. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049-2060.
7. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115:173-179.
8. Wu CK, Lin JW, Caffrey JL, Chang M-H, Hwang J-J, Lin Y-S. Cystatin C and long-term mortality among subjects with normal creatinine-based estimated glomerular filtration rates: NHANES III (Third National Health and Nutrition Examination Survey). J Am Coll Cardiol 2010; 56:1930-1936.
9. Windhausen F, Hirsch A, Fischer J, et al. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem 2009; 55:1118-1125.
10. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009; 55:1932-1943.
11. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 2008; 102:54-57.
12. Menon V, Shlipak MG, Wang X, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147:19-27.
13. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004; 110:2342-2348.
14. Eggers K, Kempf T, Venge P, Wallentin L, Wollert KC, Lindahl B. Improving long-term risk prediction in patients with acute chest pain: The Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. Am Heart J 2010; 160:88-94.
15. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
16. Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. J Am Med Assoc 2005; 294:2866-2871.
17. Bogaty P, Boyer L, Simard S, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease: the RISCA (Recurrence and Inflammation in the Acute Coronary Syndromes) study. J Am Coll Cardiol 2008; 51:2339-2346.
18. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
19. Levey AS, Stevens LA, Schmid CH, et al., for the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612.
20. Sprent P, Smeeton NC. Applied nonparametric statistical methods, 3rd ed. London: Chapman & Hall; 2001.
21. Bengtsson E, To F, Hakansson K, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25:2151-2156.
22. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. J Am Med Assoc 2004; 292:1307-1316.
23. James SK, Oldgren J, Lindback J, Johnston N, Siegbahn A, Wallentin L. An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. Am Heart J 2005; 149:619-626.
24. De Servi S,Mariani M, Mariani G, Mazzone A. C-reactive protein increase in unstable coronary disease: cause or effect? J Am Coll Cardiol 2005; 46:1496-1502.
25. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98:2370-2376.
26. Liuzzo G, Biasucci LM, Gallimore JR, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999; 34:1696-1703.
27. Pepys MB, HirshfieldGM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-1812.
28. Kilic T, Oner G, Ural E, et al. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis 2009; 207:552-558.
29. Kaski JC, Fernández-Bergé s DJ, Consuegra-Sánchez L, et al. A comparative study of biomarkers for risk prediction in acute coronary syndrome. Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis 2010; 212:636-643.